NMPA Accepts Biosimilar New Drug Application for IBI303, a Biosimilar Candidate to Humira(R) (adalimumab)
SUZHOU, China, Nov. 13, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a world-classChina-based biopharmaceutical company that develops and commercializes high quality drugs, announced today that National Medical Products Administration (NMPA, successor to CFDA) has acc...
2018-11-13 08:00
3614
Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab in Patients with First-line Squamous NSCLC at Asia Conference on Lung Cancer 2018
SUZHOU, China, Nov. 9, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 1801), a world-classChina-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical research data on cohort E from a Phase Ib clinical trial at the Internatio...
2018-11-09 15:18
2878
